EZH2/KMT6 Antibody [DyLight 405]

Product Discontinued

EZH2/KMT6 Antibody [DyLight 405] Summary

• Immunogen: Synthetic peptide made to an internal portion of the human KMT6/EZH2 protein (within residues 300-400). [Swiss-Prot# Q15910]
• Localization: Nuclear.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: EZH2
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Western Blot
• Application Notes: This KMT6/EZH2 antibody is useful for Western blot, where a band is seen ~ 85 kDa.
  
  The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Human, mouse and primate

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Immunogen affinity purified

Notes

Dylight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

Alternate Names for EZH2/KMT6 Antibody [DyLight 405]

• EC 2.1.1
• EC 2.1.1.43
• enhancer of zeste (Drosophila) homolog 2
• enhancer of zeste 2
• enhancer of zeste homolog 2 (Drosophila)
• Enhancer of zeste homolog 2
• ENX1
• ENX-1KMT6EZH1KMT6A
• EZH2
• histone-lysine N-methyltransferase EZH2
• KMT6
• Lysine N-methyltransferase 6
• MGC9169

Background

EZH2 (histone methyltransferase enhancer of zeste homolog 2) is a member of polycomb group proteins, and together with embryonic ectoderm development protein and suppressor of Zeste (SUZ12), EZH2 forms the polycomb repressor complex 2 which plays an important role in variety of biological processes such as differentiation, maintainance of cellular identity and proliferation, and stem-cell plasticity. EZH2 contains histone methyltransferase activity and mediates transcriptional repression of target genes at chromatin level by catalyzing trimethylation of histone H3 lysine 27 (H3K27me3). EZH2 is overexpressed in cancers of diverse origins that includes hematologic malignancies, urothelial/esophageal carcinoma, glioma, renal cell carcinoma, NSCLC, and colorectal, breast and hepatic cancer. Moreover, high expression of EZH2 has been linked to aggressive tumor formation/poor prognosis and EZH2 contributes to the metastasis through the downregulation of E-cadherin by mediating histone H3 methylation. Accordingly, inhibition of EZH2 expression results in significantly decreased cell proliferation and increased G2-M arrest.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: EZH2